Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 20/20 | 0.70 |
| ▸ | CBL | P22681 | 4/20 | 0.50 |
| ▸ | CBLC | Q9ULV8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24661677 | 0.95 | CBLB (0.77) | CBLBCBL | |
| SCHEMBL24660941 | 0.95 | CBLB (0.77) | CBLBCBL | |
| SCHEMBL24660931 | 0.95 | CBLB (0.77) | CBLBCBL | |
| SCHEMBL26785595 | 0.93 | CBLB (0.71) | CBLBCBL | |
| SCHEMBL26785598 | 0.93 | CBLB (0.71) | CBLBCBL | |
| SCHEMBL24661561 | 0.92 | CBLB (0.69) | CBLBCBL | |
| SCHEMBL24662846 | 0.92 | CBLB (0.69) | CBLBCBL | |
| SCHEMBL26665073 | 0.91 | CBLB (0.69) | CBLBCBL | |
| SCHEMBL24662312 | 0.91 | CBLB (0.68) | CBLBCBL | |
| SCHEMBL26665081 | 0.91 | CBLB (0.68) | CBLBCBL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| WO-2023205180-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2022221704-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | CBL, CBLB, CBLC | CBLB 2/4885CBL 1/4885CBLC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.